false
0001652935
0001652935
2025-11-21
2025-11-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities
Exchange Act of 1934
Date of report (Date of earliest event reported):
November 21, 2025
Actuate
Therapeutics, Inc.
(Exact
Name of Registrant as Specified in Charter)
| Delaware |
001-42139 |
47-3044785 |
(State or Other Jurisdiction
of Incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
1751 River Run, Suite 400
Fort Worth, Texas |
76107 |
| (Address of Principal Executive Offices) |
(Zip Code) |
(817)
887-8455
(Registrant’s Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
|
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
| Common Stock, par value $0.000001 per share |
|
ACTU |
|
The Nasdaq Stock Market LLC |
| |
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Information.
Actuate Therapeutics
Disclosure Channels to Disseminate Information
Actuate
Therapeutics’ investors and others should note that we announce material information to the public about our company and
its technologies, clinical and corporate developments, and other matters through a variety of means, including Actuate
Therapeutics’ website, press releases, SEC filings, and social media, in order to achieve broad, non-exclusionary distribution
of information to the public. We encourage our investors and others to review the information we make public in the locations below
as such information could be deemed to be material information. Please note that this list may be updated from time to time.
Interested in keeping
up with Actuate Therapeutics?
For more information
on Actuate Therapeutics and its technology, clinical and corporate developments,
and other matters, please visit: https://actuatetherapeutics.com.
For more information
for Actuate Therapeutics’ investors, including press releases, SEC
filings, corporate presentations, events, please visit: https://actuatetherapeutics.com/investors.
Investors and other interested parties can subscribe to our press releases and SEC filings at the aforementioned address.
For additional information,
please follow Actuate Therapeutics social media accounts at:
X
account (formerly Twitter): @ActuateThera or https://x.com/ActuateThera
LinkedIn:
https://www.linkedin.com/company/actuate-therapeutics-inc./
Facebook
profile: https://www.facebook.com/profile.php?id=61572431561095
Investors and other interested
parties can also subscribe to our social media accounts at the aforementioned addresses.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Actuate Therapeutics, Inc. |
| |
|
| Date: November 21, 2025 |
By: |
/s/ Daniel M. Schmitt |
| |
|
Name: Daniel M. Schmitt |
| |
|
Title: President and Chief Executive Officer |
